Published in Blood Rev on January 01, 2005
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood (2014) 1.44
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood (2014) 0.87
Molecular basis and clonal evolution of myeloproliferative neoplasms. Haematologica (2010) 0.84
Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med (2006) 0.80
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2011) 0.78
HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms. Mediators Inflamm (2015) 0.78
Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia. Thromb J (2009) 0.78
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood (2006) 2.88
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med (2007) 2.85
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood (2006) 2.74
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood (2010) 2.61
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood (2007) 2.44
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica (2008) 2.05
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood (2006) 1.89
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica (2008) 1.63
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica (2008) 1.45
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood (2008) 1.39
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood (2003) 1.35
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood (2005) 1.31
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood (2008) 1.27
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood (2012) 1.07
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica (2009) 0.99
Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells. Blood (2004) 0.97
SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood (2011) 0.92
Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica (2014) 0.87
Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood (2014) 0.86
The DEAH-box helicase RHAU is an essential gene and critical for mouse hematopoiesis. Blood (2012) 0.86
Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood (2010) 0.83
Normal erythropoiesis but severe polyposis and bleeding anemia in Smad4-deficient mice. Blood (2007) 0.82
A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem (2004) 0.80
A 2-kb c-mpl promoter fragment is sufficient to direct expression to the megakaryocytic lineage and sites of embryonic hematopoiesis in transgenic mice. Blood (2002) 0.80
Raising hematology's European voice: the importance of calling yourself a hematologist. Haematologica (2012) 0.79
Hereditary myeloproliferative disorders. Haematologica (2010) 0.77
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood (2011) 0.75
Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost (2014) 0.75
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood (2013) 0.75